Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
10+ emerging markets, Japan & ANZ transition in final phase
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Subscribe To Our Newsletter & Stay Updated